Cyclic GMP-hydrolyzing phosphodiesterases

Handbook of Experimental Pharmacology

Volumn 191, Issue , 2009, Pages 367-408

  Francis, Sharron H ^a   Corbin, Jackie D ^a   Bischoff, Erwin ^b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b BAYER PHARMA AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

1 [6 CHLORO 4 (3,4 METHYLENEDIOXYBENZYLAMINO) 2 QUINAZOLINYL] 4 PIPERIDINECARBOXYLIC ACID; 2 (4 AMINOPHENYL) 1,2 DIHYDRO 1 OXO 7 (2 PYRIDINYLMETHOXY) 4 (3,4,5 TRIMETHOXYPHENYL) 3 ISOQUINOLINECARBOXYLIC ACID METHYL ESTER; AVANAFIL; BAY 60 7550; CYCLIC GMP; DASANTAFIL; DIPYRIDAMOLE; MILRINONE; MIRODENAFIL; OXINDOLE; PHOSPHODIESTERASE; PHOSPHODIESTERASE 1 INHIBITOR; PHOSPHODIESTERASE 10 INHIBITOR; PHOSPHODIESTERASE 11 INHIBITOR; PHOSPHODIESTERASE 2 INHIBITOR; PHOSPHODIESTERASE 6 INHIBITOR; PHOSPHODIESTERASE 9 INHIBITOR; PHOSPHODIESTERASE III INHIBITOR; PHOSPHODIESTERASE INHIBITOR; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; SLX 2101; T 0156; TADALAFIL; UDENAFIL; UK 369003; UNCLASSIFIED DRUG; UNINDEXED DRUG; VARDENAFIL; VINPOCETINE; ZAPRINAST; CYCLIC AMP PHOSPHODIESTERASE; ENZYME INHIBITOR;

CATALYSIS; CENTRAL NERVOUS SYSTEM DISEASE; CONFORMATION; DRUG EFFICACY; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENCY; DRUG TARGETING; DYSPEPSIA; FEMALE SEXUAL DYSFUNCTION; FLUSHING; HEART FAILURE; HUMAN; HYDROLYSIS; NEGATIVE FEEDBACK; NONHUMAN; PEYRONIE DISEASE; PRIORITY JOURNAL; RAYNAUD PHENOMENON; REGULATORY MECHANISM; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; TISSUE DISTRIBUTION; TREATMENT INDICATION; ANIMAL; DRUG DELIVERY SYSTEM; FEEDBACK SYSTEM; METABOLISM; PHYSIOLOGY;

3',5'-CYCLIC-AMP PHOSPHODIESTERASES; ANIMALS; CYCLIC GMP; DRUG DELIVERY SYSTEMS; ENZYME INHIBITORS; FEEDBACK, BIOCHEMICAL; HUMANS; HYDROLYSIS; SIGNAL TRANSDUCTION;

EID: 61749101917     PISSN: 01712004     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-540-68964-5_16     Document Type: Review

References (214)

1. Anderson K, Stief G (1997) Neurotransmission and the contraction and relaxation of penile erectile tissues. World J Urol 14:14-20
2. Baillie G, MacKenzie SJ, Houslay MD (2001) Phorbol 12-myristate 13-acetate triggers the protein kinase A-mediated phosphorylation and activation of the PDE4D5 cAMP phosphodiesterase in human aortic smooth muscle cells through a route involving extracellular signal regulated kinase (ERK). Mol Pharmacol 60(5):1100-1111
3. Baillie GS, Sood A, McPhee I, Gall I, Perry SJ, Lefkowitz RJ, Houslay MD (2003) Beta-Arrestinmediated PDE4 cAMP phosphodiesterase recruitment regulates beta-adrenoceptor switching from Gs to Gi. Proc Natl Acad Sci USA 100(3):940-945
4. Baratti CM, Boccia MM (1999) Effects of sildenafil on long-term retention of an inhibitory avoidance response in mice. Behav Pharmacol 10(8):731-737
5. Barber R, Baillie GS, Bergmann R, Shepherd MC, Sepper R, Houslay MD, Heeke GV (2004) Differential expression of PDE4 cAMP phosphodiesterase isoforms in inflammatory cells of smokers with COPD, smokers without COPD, and nonsmokers. Am J Physiol Lung Cell Mol Physiol 287(2):L332-L343
6. Barnes AP, Livera G, Huang P, Sun C, O'Neal WK, Conti M, Stutts MJ, Milgram SL (2005) Phosphodiesterase 4D Forms a cAMP Diffusion Barrier at the Apical Membrane of the Airway Epithelium. J Biol Chem 280(9):7997-8003
7. Beard MB, Huston E, Campbell L, Gall I, McPhee I, Yarwood S, Scotland G, Houslay MD (2002) In addition to the SH3 binding region, multiple regions within the N-terminal noncatalytic portion of the cAMP-specific phosphodiesterase, PDE4A5, contribute to its intracellular targeting. Cell Signal 14(5):453-465
8. Beavo J, Houslay MD, Francis SH (2006) Cyclic nucleotide phosphodiesterase superfamily. In: Beavo J, Francis SH, Houslay MD (ed) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 3-17
9. Beavo JA, Reifsnyder DH (1990) Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11(4):150-155
10. Beltman J, Becker DE, Butt E, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA (1995) Characterization of cyclic nucleotide phosphodiesterases with cyclic GMP analogs: topology of the catalytic domains. Mol Pharmacol 47:330-339
11. Bender AT, Beavo JA (2006) Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use. Pharmacol Rev 58(3):488-520
12. Bessay EP, Zoraghi R, Blount MA, Grimes KA, Beasley A, Francis SH, Corbin JD (2007) Phosphorylation of phosphodiesterase-5 is promoted by a conformational change induced by sildenafil, vardenafil, or tadalafil. Front Biosci 12:1899-1910
13. Bessay E, Blount M, Zoraghi R, Beasley A, Grimes K, Francis S, Corbin JD (2008) Phosphorylation increases affinity of the phosphodiesterase-5 catalytic site for tadalafil. J pharmacol Exp Ther 325:62-68
14. Bischoff E (2004) Potency, selectivity, and consequences of nonselectivity of PDE inhibition. Int J Impot Res 16(Suppl 1):S11-S14
15. Blokland A, Schreiber R, Prickaerts J (2006) Improving memory: a role for phosphodiesterases. Curr Pharm Des 12(20):2511-2523
16. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66(1):144-152
17. Blount MA, Zoraghi R, Ke H, Bessay EP, Corbin JD, Francis SH (2006) A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization. Mol Pharmacol 70(5):1822-1831
18. Blount MA, Zoraghi R, Bessay EP, Beasley A, Francis SH, Corbin JD (2007) Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors. J Pharmacol Exp Ther 323(2):730-737
19. Boess FG, Hendrix M, van der Staay FJ, Erb C, Schreiber R, van Staveren W, de Vente J, Prickaerts J, Blokland A, Koenig G (2004) Inhibition of phosphodiesterase 2 increases neuronal cGMP, synaptic plasticity and memory performance. Neuropharmacology 47(7):1081-1092.
20. Bolger GB (2006) Phosphodiesterase isoforms-an annotate list. In: Beavo J, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease). CRC Press, Boca Raton, pp 19-31
21. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8(2):47-52
22. Borlaug BA, Melenovsky V, Marhin T, Fitzgerald P, Kass DA (2005) Sildenafil inhibits betaadrenergic- stimulated cardiac contractility in humans. Circulation 112(17):2642-2649.
23. Broughton BJ, Chaplen P, Knowles P, Lunt E, Pain DL, Wooldridge KR, Ford R, Marshall S, Walker JL, Maxwell DR (1974) New inhibitor of reagin-mediated anaphylaxis. Nature 251(5476):650-652
24. Burgers PM, Eckstein F, Hunneman DH, Baraniak J, Kinas RW, Lesiak K, Stec WJ (1979) Stereochemistry of hydrolysis of adenosine 3':5'-cyclic phosphorothioate by the cyclic phosphodiesterase from beef heart. J Biol Chem 254(20):9959-9961
25. Burnett A (2006) Erectile dysfunction. J Urol 175:25-31
26. Burnett AL (2002) Nitric oxide regulation of penile erection: biology and therapeutic implications. J Androl 23(5):S20-26
27. Burns F, Zhao AZ, Beavo JA (1996) Cyclic nucleotide phosphodiesterases: gene complexity, regulation by phosphorylation, and physiological implications. [Review] [107 refs]. Adv Pharmacol (N Y) 36:29-48
28. Bush PA, Aronson WJ, Buga GM, Rajfer J, Ignarro LJ (1992) Nitric oxide is a potent relaxant of human and rabbit corpus cavernosum. J Urol 147(6):1650-1655
29. Butcher RW, Sutherland EW (1962) Adenosine 3',5'-phosphate in biological materials: I. Purification and properties of cyclic 3',5'-nucleotide phosphodiesterase and use of this enzyme to characterize adenosine 3',5'-phosphate in human urine. J Biol Chem 237:1244-1250
30. Butt E, Beltman J, Becker DE, Jensen GS, Rybalkin SD, Jastorff B, Beavo JA (1995) Characterization of cyclic nucleotide phosphodiesterases with cyclic AMP analogs: topology of the catalytic sites and comparison with other cyclic AMP-binding proteins. Mol Pharmacol 47:340-347
31. Caglayan E, Huntgeburth M, Karasch T, Weihrauch J, Hunzelmann N, Krieg T, Erdmann E, Rosenkranz S (2006) Phosphodiesterase type 5 inhibition is a novel therapeutic option in Raynaud disease. Arch Intern Med 166(2):231-233
32. Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY (2005) A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23(2):201-207
33. Carson CC, Lue TF (2005) Phosphodiesterase type 5 inhibitors for erectile dysfunction. BJU Int 96(3):257-280
34. Castro LR, Verde I, Cooper DM, Fischmeister R (2006) Cyclic guanosine monophosphate compartmentation in rat cardiac myocytes. Circulation 113(18):2221-2228
35. Charbonneau H, Beier N, Walsh KA, Beavo JA (1986) Identification of a conserved domain among cyclic nucleotide phosphodiesterases from diverse species. Proc Natl Acad Sci USA 83: 9308-9312
36. Conti M, Beavo J (2007) Biochemistry and physiology of cyclic nucleotide phosphodiesterases: essential components in cyclic nucleotide signaling. Annu Rev Biochem 76:481-511
37. Conti M, Richter W, Mehats C, Livera G, Park JY, Jin C (2003) Cyclic AMP-specific PDE4 phosphodiesterases as critical components of cyclic AMP signaling. J Biol Chem 278(8):5493-5496
38. Corbin JD, Francis SH (1999) Cyclic GMP phosphodiesterase-5: target of sildenafil. J Biol Chem 274(20):13729-13732
39. Corbin JD, Beebe SJ, Blackmore PF (1985) cAMP-dependent protein kinase activation lowers hepatocyte cAMP. J Biol Chem 260(15):8731-8735
40. Corbin JD, Turko IV, Beasley A, Francis SH (2000) Phosphorylation of phosphodiesterase-5 by cyclic nucleotide-dependent protein kinase alters its catalytic and allosteric cGMP-binding activities. Eur J Biochem/FEBS 267(9):2760-2767
41. Corbin J, Blount MA,Weeks JL, Beasley A, Kuhn KP, Ho SJ, Saidi LF, Hurley JH, J. K, Francis S (2003) [3H]sildenafil binding to Phosphodiesterase-5 Is Specific, Kinetically Heterogenous, and Stimulated by cGMP. Mol Pharmacol 63(6):1364-1372
42. Corbin JD, Beasley A, Blount MA, Francis SH (2004) Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5). Neurochem Int 45(6):859-863
43. Corbin JD, Beasley A, Blount MA, Francis SH (2005) High lung PDE5: a strong basis for treating pulmonary hypertension with PDE5 inhibitors. Biochem Biophys Res Commun 334(3): 930-938
44. Corbin J, Francis S, Zoraghi R (2006) Tyrosine-612 in PDE5 contributes to higher affinity for vardenafil over sildenafil. Int J Impot Res 18(3):251-257
45. Coskran TM, Morton D, Menniti FS, Adamowicz WO, Kleiman RJ, Ryan AM, Strick CA, Schmidt CJ, Stephenson DT (2006) Immunohistochemical localization of phosphodiesterase 10A in multiple mammalian species. J Histochem Cytochem 54(11):1205-1213
46. Cote RH (2006) Photoreceptor phosphodiesterase (PDE6): A G-protein-activated PDE regulating visual excitation in rod and cone photoreceptor cells. In: Beavo J, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 165-193
47. D'Sa C, Tolbert LM, ContiM, Duman RS (2002) Regulation of cAMP-specific phosphodiesterases type 4B and 4D (PDE4) splice variants by cAMP signaling in primary cortical neurons. J Neurochem 81(4):745-757
48. Dangrell S (2005) Comparison of clinical trials with sildenafil, vardenafil and tadalafil in erectile dysfunction. Exp Opin Pharmacother 6:75-84
49. Das A, Xi L, Kukreja RC (2005) Phosphodiesterase-5 inhibitor sildenafil preconditions adult cardiac myocytes against necrosis and apoptosis. Essential role of nitric oxide signaling. J Biol Chem 280(13):12944-12955
50. Degerman E, Smith CJ, Tornqvist H, Vasta V, Belfrage P, Manganiello VC (1990) Evidence that insulin and isoprenaline activate the cGMP- inhibited low-Km cAMP phosphodiesterase in rat fat cells by phosphorylation. Proc Natl Acad Sci USA 87:533-537
51. Degerman E, Belfrage PManganiello VC (1996) cGMP-inhibited phosphodiesterases (PDE3 gene family). Biochem Soc Trans 24:1010-1014
52. Degerman E, Belfrage P Manganiello VC (1997) Structure, localization, and regulation of cGMPinhibited phosphodiesterase (PDE3). [Review] [61 refs]. J Biol Chem 272(11):6823-6826
53. Devan BD, Bowker JL, Duffy KB, Bharati IS, Jimenez M, Sierra-Mercado D, Jr., Nelson CM, Spangler EL, Ingram DK (2006) Phosphodiesterase inhibition by sildenafil citrate attenuates a maze learning impairment in rats induced by nitric oxide synthase inhibition. Psychopharmacology (Berl) 183(4):439-445
54. Erguden J-K, Bauser M, Burkhardt N, Flubacher D, Friedl A, Hinz V, Jork R, Naab P, Niewohner U, Repp T-O, Schlemmer K-H, Stoltefuss J, Bruckner D, Hendrix M, Schauss D, Tersteegen A (2003) Preparation of imidazotriazines as phosphodiesterase 10A inhibitors for the treatment of neurodengenerative diseases., WO 03/00693 Bayer
55. Erneux C, Couchie D, Dumont JE, Jastorff B (1984) Cyclic nucleotide derivatives as probes of phosphodiesterase catalytic and regulatory sites. Adv Cyclic Nucleotide Protein Phosphorylation Res 16:107-118
56. Fawcett L, Baxendale R, Stacey P, McGrouther C, Harrow I, Soderling S, Hetman J, Beavo JA, Phillips SC (2000) Molecular cloning and characterization of a distinct human phosphodiesterase gene family: PDE11A. Proc Natl Acad Sci USA 97(7):3702-3707
57. Ferrini MG, Vernet D, Magee TR, Shahed A, Qian A, Rajfer J, Gonzalez-Cadavid NF (2002) Antifibrotic role of inducible nitric oxide synthase. Nitric Oxide 6(3):283-294
58. Ferrini MG, Davila HH, Kovanecz I, Sanchez SP, Gonzalez-Cadavid NF, Rajfer J (2006) Vardenafil prevents fibrosis and loss of corporal smooth muscle that occurs after bilateral cavernosal nerve resection in the rat. Urology 68(2):429-435
59. Filippi S, Morelli A, Sandner P, Fibbi B, Mancina R, Marini M, Gacci M, Vignozzi L, Barbara Vannelli G, Carini M, Forti G, Maggi M (2006) Characterization and functional role of an androgen-dependent PDE-5 activity in bladder. Endocrinology 148:1019-1029.
60. Fink TL, Francis SH, Beasley A, Grimes KA, Corbin JD (1999) Expression of an active, monomeric catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase (PDE5). J Biol Chem 274(49):34613-34620
61. Fischmeister R, Castro L, Abi-Gerges A, Rochais F, Vandecasteele G (2005) Species- and tissuedependent effects of NO and cyclic GMP on cardiac ion channels. Comp Biochem Physiol 142(2):136-143
62. Fischmeister R, Castro LR, Abi-Gerges A, Rochais F, Jurevicius J, Leroy J, Vandecasteele G (2006) Compartmentation of cyclic nucleotide signaling in the heart: the role of cyclic nucleotide phosphodiesterases. Circ Res 99(8):816-828
63. Fisher PW, Salloum F, Das A, Hyder H, Kukreja RC (2005) Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation 111(13):1601-1610
64. Foresta C, Lana A, Cabrelle A, Ferigo M, Caretta N, Garolla A, Palu G, Ferlin A (2005) PDE- 5 inhibitor, Vardenafil, increases circulating progenitor cells in humans. Int J Impot Research 17(4):377-380.
65. Francis SH, Corbin JD (2005) Phosphodiesterase-5 inhibition: the molecular biology of erectile function and dysfunction. Urol Clin North Am 32(4):419-429, vi.
66. Francis SH, Thomas MK, Corbin JD (1990) Cyclic GMP-binding cyclic GMP-specific phosphodiesterase from lung. In: Beavo J, Houslay MD (eds) Cyclic nucleotide phosphodiesterases: structure, regulation, and drug action. Wiley, New York, pp 117-140
67. Francis SH, Colbran JL, McAllister-Lucas LM, Corbin JD (1994) Zinc interactions and conserved motifs of the cGMP-binding cGMP- specific phosphodiesterase suggest that it is a zinc hydrolase. J Biol Chem 269:22477-22480
68. Francis SH, Chu DM, Thomas MK, Beasley A, Grimes K, Busch JL, Turko IV, Haik TL, Corbin JD (1998) Ligand-induced conformational changes in cyclic nucleotide phosphodiesterases and cyclic nucleotide-dependent protein kinases. Methods 14(1):81-92
69. Francis SH, Turko IV, Grimes KA, Corbin JD (2000) Histidine-607 and histidine-643 provide important interactions for metal support of catalysis in phosphodiesterase-5. Biochemistry 39:9591-9596
70. Francis SH, Turko IV, Corbin JD (2001) Cyclic nucleotide phosphodiesterases: relating structure and function. Prog Nucleic Acid Res Mol Biol 65:1-52
71. Francis SH, Zoraghi R, Kotera J, Ke H, Bessay EP, Blount MA, Corbin JD (2006) Phosphodiesterase-5: molecular characteristics relating to structure, function, and regulation. In: Beavo J, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 131-164
72. Freedman R, Girgis R, Mayes M (1999) Acute effect of nitric oxide on Raynaud's phenomenon in scleroderma. Lancet 354:739
73. Fries R, Shariat K, von Wilmowsky H, Bohm M (2005) Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Circulation 112(19):2980-2985
74. Frossard N, Landry Y, Pauli G, Ruckstuhl M (1981a) Effects of cyclic AMP- and cyclic GMPphosphodiesterase inhibitors on immunological release of histamine and on lung contraction. Br J Pharmacol 73(4):933-938
75. Frossard N, Pauli G Landry Y (1981b) Inhibition of antigen-induced histamine release from rat mast cells by a cyclic GMP-phosphodiesterase inhibitor and sodium nitrite. Agents Actions 11(6-7):653-654
76. Galie N, Ghofrani HA, Torbicki A, Barst RJ, Rubin LJ, Badesch D, Fleming T, Parpia T, Burgess G, Branzi A, Grimminger F, Kurzyna M, Simonneau G (2005) Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med 353(20):2148-2157
77. Ghofrani HA, Olschewski H, Seeger W, Grimminger F (2002) [Sildenafil for treatment of severe pulmonary hypertension and commencing right-heart failure]. Pneumologie 56(11):665-672
78. Ghofrani HA, Pepke-Zaba J, Barbera JA, Channick R, Keogh AM, Gomez-Sanchez MA, Kneussl M, Grimminger F (2004) Nitric oxide pathway and phosphodiesterase inhibitors in pulmonary arterial hypertension. J Am Coll Cardiol 43(12 Suppl S):68S-72S
79. Goldberg ND, Walseth TF, Stephenson JH, Krick TP, Graff G (1980) 18O-Labeling of guanosine monophosphate upon hydrolysis of cyclic guanosine 3' : 5'-monophosphate by phosphodiesterase. J Biol Chem 255:10344-10347
80. Gopal VK, Francis SH, Corbin JD (2001) Allosteric sites of phosphodiesterase-5 (PDE5). A potential role in negative feedback regulation of cGMP signaling in corpus cavernosum. Eur J Biochem/FEBS 268(11):3304-3312
81. Guazzi M, SamajaM(2007) The role of PDE5 inhibitors in cardiopulmonary disorders: from basic evidence to clinical development. Curr Med Chem 14:2181-2191
82. Guo J, Williams DJ, Puhl HL,III, Ikeda SR (2008) Inhibition of N-type calcium channels by activation of GPR35, an orphan receptor, heterologously expressed in rat sympathetic neurons. J Pharmacol Exp Ther 324(1):342-351
83. Haning H, Niewohner U, Schenke T, Es-Sayed M, Schmidt G, Lampe T, Bischoff E (2002) Imidazo[5,1-f]triazin-4(3H)-ones, a new class of potent PDE 5 inhibitors. Bioorg Med Chem Lett 12(6):865-868
84. Haning H, Niewohner U, Bischoff E (2003) Phosphodiesterase type 5 (PDE5) inhibitors. ProgMed Chem 41:249-306
85. Hassan MA, Ketat AF (2005) Sildenafil citrate increases myocardial cGMP content in rat heart, decreases its hypertrophic response to isoproterenol and decreases myocardial leak of creatine kinase and troponin T. BMC Pharmacol 5(1):10
86. Hendrix M, Kallus C (2004) Phosphodiesterase inhibitors: a chemgenomic view. In Chemogenomics in Drug Discovery pp 243-288
87. Hepp R, Tricoire L, Hu E, Gervasi N, Paupardin-Tritsch D, Lambolez B, Vincent P (2007) Phosphodiesterase type 2 and the homeostasis of cyclic GMP in living thalamic neurons. J Neurochem 102(6):1875-1886
88. Hirata K, Adji A, Vlachopoulos C, O'Rourke MF (2005) Effect of sildenafil on cardiac performance in patients with heart failure. Am J Cardiol 96(10):1436-1440
89. Hoffmann R, Baillie GS, MacKenzie SJ, Yarwood SJ, Houslay MD (1999) The MAP kinase ERK2 inhibits the cyclic AMP-specific phosphodiesterase HSPDE4D3 by phosphorylating it at Ser579. Embo J 18(4):893-903
90. Houslay MD, Adams DR (2003) PDE4 cAMP phosphodiesterases: modular enzymes that orchestrate signalling cross-talk, desensitization and compartmentalization. Biochem J 370(Pt 1):1-18
91. Houslay MD, Milligan G (1997) Tailoring cAMP-signalling responses through isoform multiplicity. [Review] [49 refs]. Trends Biochem Sci 22(6):217-224
92. Hryniewicz K, Dimayuga C, Hudaihed A, Androne AS, Zheng H, Jankowski K, Katz SD (2005) Inhibition of angiotensin-converting enzyme and phosphodiesterase type 5 improves endothelial function in heart failure. Clin Sci (Lond) 108(4):331-338
93. Huai Q, Liu Y, Francis SH, Corbin JD, Ke H (2004) Crystal structures of phosphodiesterases 4 and 5 in complex with inhibitor 3-isobutyl-1-methylxanthine suggest a conformation determinant of inhibitor selectivity. J Biol chem 279(13):13095-13101
94. Ignarro LJ, Bush PA, Buga GM, Wood KS, Fukuto JM, Rajfer J (1990) Nitric oxide and cyclic GMP formation upon electrical field stimulation cause relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170(2):843-850
95. Ishiwata N, Noguchi K, Kawanishi M, Asakura Y, Hori M, Mitani A, Ito Y, Takahashi K, Nishiyama H, Shudo N, Takahashi S, Takahashi K, Tsuruzoe N, Nakaike S (2007) NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication model. Life Sci 81(12):970-978
96. Jarvest RL, Lowe G, Baraniak J, Stec WJ (1982) A stereochemical investigation of the hydrolysis of cyclic AMP and the (Sp)-and (Rp)-diastereoisomers of adenosine cyclic 3':5'-phosphorothioate by bovine heart and baker's-yeast cyclic AMP phosphodiesterases. Biochem J 203(2):461-470
97. Jin SL, Conti M (2002) Induction of the cyclic nucleotide phosphodiesterase PDE4B is essential for LPS-activated TNF-alpha responses. Proc Natl Acad Sci USA 99(11):7628-7633
98. Kapur V, Schwarz E (2007) The relationship between erectile dysfunction and cardiovascular disease Part I: pathophysiology and mechanisms. Rev Cardiovasc Med Fall 8:214-219
99. Karpen JW, Rich TC (2001) The fourth dimension in cellular signaling. Science 293(5538): 2204-2205
100. Kass DA, Takimoto E, Nagayama T, Champion HC (2007) Phosphodiesterase regulation of nitric oxide signaling. Cardiovasc Res 75(2):303-314
101. Katz SD, Balidemaj K, Homma S, Wu H, Wang J, Maybaum S (2000) Acute type 5 phosphodiesterase inhibition with sildenafil enhances flow-mediated vasodilation in patients with chronic heart failure. J Am Coll Cardiol 36(3):845-851
102. Ke H, Wang H (2006) Structure, catalytic mechanism, and inhibitor selectivity of cyclic nucleotide phosphodiesterases. In: Beavo J, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 607-625
103. Kim Y, Yoo M, Lee M (2005) DA-8159-Udenafil. Drugs Future 30:678-682
104. Kotera J, Omori K (2006) PDE9. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC, Boca Raton, pp 221-235
105. Laliberte F, Han Y, Govindarajan A, Giroux A, Liu S, Bobechko B, Lario P, Bartlett A, Gorseth E, Gresser M, Huang Z (2000) Conformational difference between PDE4 apoenzyme and holoenzyme. Biochemistry 39(21):6449-6458
106. Laliberte F, Liu S, Gorseth E, Bobechko B, Bartlett A, Lario P, GresserMJ, Huang Z (2002) In vitro PKA phosphorylation-mediated human PDE4A4 activation. FEBS Lett 512(1-3):205-208
107. Lebel L, Menniti S, Schmidt C (2003) US2003/32579, Pfizer
108. Lim J, Pahlke G, Conti M (1999) Activation of the cAMP-specific phosphodiesterase PDE4D3 by phosphorylation. Identification and function of an inhibitory domain. J Biol Chem 274(28):19677-19685
109. Liu S, Laliberte F, Bobechko B, Bartlett A, Lario P, Gorseth E, Van Hamme J, Gresser MJ, Huang Z (2001) Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors. Biochemistry 40(34):10179-10186
110. Loughney K, Hill TR, Florio VA, Uher L, Rosman GJ, Wolda SL, Jones BA, Howard ML, McAllister-Lucas LM, SonnenburgWK, Francis SH, Corbin JD, Beavo JA, Ferguson K (1998) Isolation and characterization of cDNAs encoding PDE5A, a human cGMP-binding, cGMPspecific 3,5-cyclic nucleotide phosphodiesterase. Gene 216(1):139-147
111. Loughney K, Taylor J, Florio VA (2005) 3,5-cyclic nucleotide phosphodiesterase 11A: localization in human tissues. Int J Impot Res 17(4):320-325
112. Lue TF (2000) Erectile dysfunction. N Engl J Med 342(24):1802-1813
113. Lugnier C, Schoeffter P, Le Bec A, Strouthou E, Stoclet JC (1986) Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta. Biochem Pharmacol 35(10):1743-1751
114. MacFarland RT, Zelus BD, Beavo JA (1991) High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells. J Biol Chem 266(1):136-142
115. Martinez SE (2006) PDE2 Structure and functions. In: Beavo JA, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterases in health and disease. CRC Press, Boca Raton, pp 55-77
116. Martinez SE, Bruder S, Schultz A, Zheng N, Schultz JE, Beavo JA, Linder JU (2005) Crystal structure of the tandem GAF domains from a cyanobacterial adenylyl cyclase: modes of ligand binding and dimerization. Proc Natl Acad Sci USA 102(8):3082-3087
117. Maurice DH (2003) Dynamic regulation of cAMP signaling by cGMP in the cardiovascular system: roles of phosphodiesterase 2 and phosphodiesterase 3 enzymes. ProcWest Pharmacol Soc 46:32-36
118. Maurice DH (2005) Cyclic nucleotide phosphodiesterase-mediated integration of cGMP and cAMP signaling in cells of the cardiovascular system. Front Biosci 10:1221-1228
119. Maurice DH, Crankshaw D, Haslam RJ (1991) Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscle. Eur J Pharmacol 192(2):235-242
120. McAllister-Lucas LM, Sonnenburg WK, Kadlecek A, Seger D, LeTrong H, Colbran JL, Thomas MK, Walsh KA, Francis SH, Corbin JD, Beavo JA (1993) The structure of a bovine lung cGMP-binding, cGMP-specific phosphodiesterase deduced from a cDNA clone. J Biol Chem 268:22863-22873
121. McVary K, Monnig W, Jr JC, Young J, Tseng L, Ende Gvd (2007a) Sildenafil citrate improves erectile function and urinary symptoms in men with erectile dysfunction and lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized, double-blind trial. J Urol 177:1071-1077
122. McVary KT, Roehrborn CG, Kaminetsky JC, Auerbach SM, Wachs B, Young JM, Esler A, Sides GD, Denes BS (2007b) Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 177(4):1401-1407
123. Mehats C, Andersen C, Filopanti M, Jin SL, Conti M (2002) Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling. Trends Endocrinol Metab 13(1):29-35
124. Menniti FS, Faraci WS, Schmidt CJ (2006) Phosphodiesterases in the CNS: targets for drug development. Nat Rev Drug Discov 5(8):660-670
125. Mullershausen F, Friebe A, Feil R, Thompson WJ, Hofmann F, Koesling D (2003) Direct activation of PDE5 by cGMP: long-term effects within NO/cGMP signaling. J Cell Biol 160(5):719-727
126. Nehra A, Barrett DM, Moreland RB (1999) Pharmacotherapeutic advances in the treatment of erectile dysfunction. Mayo Clin Proc 74(7):709-721
127. Niewoehner U, Ergueden J-K, Bauser M, Burkhardt N, Flubacher D, Friedl A, Gerlach I, Hinz V, Jork R, Naab P, Repp T-O, Schlemmer K-H, Stoltefuss J (2003) Novel use for PDE11A inhibitors, WO 03/00269 Bayer.
128. Oelke M, Hedlund P, Albrecht K, Ellinghaus P, Stief CG, Jonas U, Andersson KE, Uckert S (2006) Expression of cAMP and cGMP-phosphodiesterase isoenzymes 3, 4, and 5 in the human clitoris:immunohistochemical and molecular biology study. Urology 67(5):1111-1116
129. Oki N, Takahashi SI, Hidaka H, Conti M (2000) Short term feedback regulation of cAMP in FRTL-5 thyroid cells. Role of PDE4D3 phosphodiesterase activation. J Biol Chem 275(15):10831-10837
130. Omburo GA, Brickus T, Ghazaleh FA, Colman RW (1995) Divalent metal cation requirement and possible classification of cGMP-inhibited phosphodiesterase as a metallohydrolase. Arch Biochem Biophys 323(1):1-5
131. Padma-Nathan H, McMurray JG, Pullman WE, Whitaker JS, Saoud JB, Ferguson KM, Rosen RC (2001) On-demand IC351 (Cialis) enhances erectile function in patients with erectile dysfunction. Int J Impot Res 13(1):2-9
132. Park K, Moreland RB, Goldstein I, Atala A, Traish A (1998) Sildenafil inhibits phosphodiesterase type 5 in human clitoral corpus cavernosum smooth muscle. Biochem Biophys Res Commun 249(3):612-617
133. Podzuweit T, Nennstiel P, Muller A (1995) Isozyme selective inhibition of cGMP-stimulated cyclic nucleotide phosphodiesterases by erythro-9-(2-hydroxy-3- nonyl) adenine. Cell signal 7(7):733-738
134. Pope J (2007) The diagnosis and treatment of Raynaud's phenomenon: a practical approach. Drugs 67:517-525
135. Prickaerts J, van StaverenWC, Sik A, Markerink-van Ittersum M, Niewohner U, van der Staay FJ, Blokland A, de Vente J (2002) Effects of two selective phosphodiesterase type 5 inhibitors, sildenafil and vardenafil, on object recognition memory and hippocampal cyclic GMP levels in the rat. Neuroscience 113(2):351-361
136. Prickaerts J, Sik A, van Staveren WC, Koopmans G, Steinbusch HW, van der Staay FJ, de Vente J, Blokland A (2004) Phosphodiesterase type 5 inhibition improves early memory consolidation of object information. Neurochem Int 45(6):915-928
137. Rajfer J, Aronson WJ, Bush PA, Dorey FJ, Ignarro LJ (1992) Nitric oxide as a mediator of relaxation of the corpus cavernosum in response to nonadrenergic, noncholinergic neurotransmission. N Engl J Med 326(2):90-94
138. Rall TW, Sutherland EW (1958) Formation of a cyclic adenine ribonucleotide by tissue particles. J Biol Chem 232:1065-1076
139. Ravipati G, McClung J, Aronow W, Peterson S, Frishman W (2007) Type 5 phosphodiesteras inhibitors in the treatment of erectile dysfunction and cardiovascular disease. Cardiol Rev 15: 76-86
140. Rodefer JS, Murphy ER, Baxter MG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci 21(4):1070-1076
141. Rotella DP (2002) Phosphodiesterase 5 inhibitors: current status and potential applications. Nat Rev Drug Discov 1(9):674-682
142. Rotella DP (2003) Tadalafil Lilly ICOS. Curr Opin Invest Drugs 4(1):60-65
143. Rybalkin SD, Bornfeldt KE, Sonnenburg WK, Rybalkina IG, Kwak KS, Hanson K, Krebs EG, Beavo JA (1997) Calmodulin-stimulated cyclic nucleotide phosphodiesterase (PDE1C) is induced in human arterial smooth muscle cells of the synthetic, proliferative phenotype. J Clin Invest 100(10):2611-2621
144. Rybalkin SD, Rybalkina IG, Feil R, Hofmann F, Beavo JA (2002) Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J biol chem 277(5):3310-3317
145. Rybalkin SD, Rybalkina IG, Shimizu-Albergine M, Tang XB, Beavo JA (2003) PDE5 is converted to an activated state upon cGMP binding to the GAF A domain. Embo J 22(3):469-478
146. Sandner P, Hutter J, Tinel H, Ziegelbauer K, Bischoff E (2007) PDE5 inhibitors beyond erectile dysfunction. Int J Impot Res 19(6):533-543
147. Sandner P, Svenstrup N, Tinel H, Haning H, Bischoff E (2008) Phosphodiesterase 5 inhibitors and erectile dysfunction. Expert Opin Ther Pat 18(1):21-33
148. Sastry BK, Narasimhan C, Reddy NK, Raju BS (2004) Clinical efficacy of sildenafil in primary pulmonary hypertension: a randomized, placebo-controlled, double-blind, crossover study. J Am Coll Cardiol 43(7):1149-1153
149. Scapin G, Patel SB, Chung C, Varnerin JP, Edmondson SD, Mastracchio A, Parmee ER, Singh SB, Becker JW, Van der Ploeg LH, Tota MR (2004) Crystal structure of human phosphodiesterase 3B: atomic basis for substrate and inhibitor specificity. Biochemistry 43(20):6091-6100
150. Schermuly RT, Kreisselmeier KP, Ghofrani HA, Yilmaz H, Butrous G, Ermert L, Ermert M, Weissmann N, Rose F, Guenther A, Walmrath D, Seeger W, Grimminger F (2004) Chronic sildenafil treatment inhibits monocrotaline-induced pulmonary hypertension in rats. Am J Respir Crit Care Med 169(1):39-45
151. Schultheiss D, Stief C (1999) Physiology and pathophysiology of erection: consequences for present medical therapy of rerectile dysfunction. Andrologia 31 (Suppl 1):59-64
152. Sebkhi A, Strange JW, Phillips SC, Wharton J, Wilkins MR (2003) Phosphodiesterase type 5 as a target for the treatment of hypoxia-induced pulmonary hypertension. Circulation 107(25):3230-3235
153. Seeger TF, Bartlett B, Coskran TM, Culp JS, James LC, Krull DL, Lanfear J, Ryan AM, Schmidt CJ, Strick CA, Varghese AH, Williams RD, Wylie PG, Menniti FS (2003) Immunohistochemical localization of PDE10A in the rat brain. Brain Res 985(2):113-126
154. Sekhar KR, Grondin P, Francis SH, Corbin JD (1996) Design and synthesis of xanthines and cyclic GMP analogues as potent inhibitors of PDE5. In: Schudt C, Dent G, Rabe KF (eds) Phosphodiesterase inhibitors. Academic Press, New York, pp 135-146
155. Senzaki H, Smith CJ, Juang GJ, Isoda T, Mayer SP, Ohler A, Paolocci N, Tomaselli GF, Hare JM, Kass DA (2001) Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure. FASEB J 15(10):1718-1726
156. Sette C, Conti M (1996) Phosphorylation and activation of a cAMP-specific phosphodiesterase by the cAMP-dependent protein kinase. Involvement of serine 54 in the enzyme activation. J Biol Chem 271(28):16526-16534
157. Seybold J, Thomas D, Witzenrath M, Boral S, Hocke AC, Burger A, Hatzelmann A, Tenor H, Schudt C, Krull M, Schutte H, Hippenstiel S, Suttorp N (2005) Tumor necrosis factor-alphadependent expression of phosphodiesterase 2: role in endothelial hyperpermeability. Blood 105(9):3569-3576
158. Shakur Y, Takeda K, Kenan Y, Yu ZX, Rena G, Brandt D, Houslay MD, Degerman E, Ferrans VJ, Manganiello VC (2000) Membrane localization of cyclic nucleotide phosphodiesterase 3 (PDE3). Two N-terminal domains are required for the efficient targeting to, and association of, PDE3 with endoplasmic reticulum. J Biol Chem 275(49):38749-38761
159. Shakur Y, Holst LS, Landstrom TR,Movsesian M, Degerman E, Manganiello V (2001) Regulation and function of the cyclic nucleotide phosphodiesterase (PDE3) gene family. Prog Nucleic Acid Res Mol Biol 66:241-277
160. Shepherd MC, Baillie GS, Stirling DI, HouslayMD (2004) Remodelling of the PDE4 cAMP phosphodiesterase isoform profile upon monocyte-macrophage differentiation of human U937 cells. Br J Pharmacol 142(2):339-351
161. Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ (2006) Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis. Neuropharmacology 51(2):386-396 SK Chemicals (2001) WO 2001060825
162. Snyder PB, Esselstyn JM, Loughney K, Wolda SL, Florio VA (2005) The role of cyclic nucleotide phosphodiesterases in the regulation of adipocyte lipolysis. J Lipid Res 46(3):494-503
163. Soderling SH, Beavo JA (2000) Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions. Curr Opin Cell Biol 12(2):174-179
164. Soderling SH, Bayuga SJ, Beavo JA (1998) Identification and characterization of a novel family of cyclic nucleotide phosphodiesterases. J Biol Chem 273(25):15553-15558
165. Soderling SH, Bayuga SJ, Beavo JA (1999) Isolation and characterization of a dual-substrate phosphodiesterase gene family: PDE10A. Proc Natl Acad Sci USA 96(12):7071-7076
166. Sonnenburg WK, Seger D, Kwak KS, Huang J, Charbonneau H, Beavo JA (1995) Identification of inhibitory and calmodulin-binding domains of the PDE1A1 and PDE1A2 calmodulinstimulated cyclic nucleotide phosphodiesterases. J Biol Chem 270(52):30989-31000
167. Stacey P, Rulten S, Dapling A, Phillips SC (1998) Molecular cloning and expression of human cGMP-binding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 247(2):249-254
168. Stief CG, Porst H, Neuser D, Beneke M, Ulbrich E (2008) A Randomised, Placebo-Controlled Study to Assess the Efficacy of Twice-Daily Vardenafil in the Treatment of Lower Urinary Tract Symptoms Secondary to Benign Prostatic Hyperplasia. Eur Urol 53(6):1236-1244
169. Sung BJ, Hwang KY, Jeon YH, Lee JI, Heo YS, Kim JH, Moon J, Yoon JM, Hyun YL, Kim E, Eum SJ, Park SY, Lee JO, Lee TG, Ro S, Cho JM (2003) Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules. Nature 425(6953):98-102
170. Taher A, Meyer M, Stief CG, Jonas U, ForssmannWG(1997) Cyclic nucleotide phosphodiesterase in human cavernous smooth muscle. World J Urol 15(1):32-35
171. Takahashi T, Kanda T, Inoue M, Suzuki T, Kobayashi I, Kodama K, Nagai R (1996) A selective type V phosphodiesterase inhibitor, E4021, protects the development of right ventricular overload and medial thickening of pulmonary arteries in a rat model of pulmonary hypertension. Life Sci 59(23):PL371-PL377
172. Takahashi SI, Nedachi T, Fukushima T, Umesaki K, Ito Y, Hakuno F, Van Wyk JJ, Conti M (2001) Long-term hormonal regulation of the cAMP-specific phosphodiesterases in cultured FRTL-5 thyroid cells. Biochim Biophys Acta 1540(1):68-81
173. Takimoto E, Champion HC, Belardi D, Moslehi J, Mongillo M, Mergia E, Montrose DC, Isoda T, Aufiero K, Zaccolo M, Dostmann WR, Smith CJ, Kass DA (2005a) cGMP catabolism by phosphodiesterase 5A regulates cardiac adrenergic stimulation by NOS3-dependent mechanism. Circ Res 96(1):100-109
174. Takimoto E, Champion HC, Li M, Belardi D, Ren S, Rodriguez ER, Bedja D, Gabrielson KL, Wang Y, Kass DA (2005b) Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 11(2):214-222
175. Takimoto E, Belardi D, Tocchetti CG, Vahebi S, Cormaci G, Ketner EA, Moens AL, Champion HC , Kass DA (2007) Compartmentalization of cardiac beta-adrenergic inotropy modulation by phosphodiesterase type 5. Circulation 115(16):2159-2167
176. Taniguchi Y, Tonai-Kachi H, Shinjo K (2006) Zaprinast, a well-known cyclic guanosine monophosphate-specific phosphodiesterase inhibitor, is an agonist for GPR35. FEBS Lett 580(21):5003-5008
177. Tejada ID (2004) Therapeutic strategies for optimizing PDE5 inhibitor therapy in patients with erectile dysfunction considered difficult or challenging to treat. Int J Impot Res 216:40-42
178. Thomas MK, Francis SH, Corbin JD (1990) Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J Biol Chem 265(25):14971-14978
179. Tinel H, Stelte-Ludwig B, Hutter J, Sandner P (2006) Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms. BJU Int 98(6):1259-1263
180. Trigo-Rocha F, Aronson WJ, Hohenfellner M, Ignarro LJ, Rajfer J, Lue TF (1993) Nitric oxide and cGMP: mediators of pelvic nerve-stimulated erection in dogs. Am J Physiol 264(2 Pt 2): H419-H422
181. Trigo-Rocha F, Hsu GL, Donatucci CF, Martinez-Pineiro L, Lue TF, Tanagho EA (1994) Intracellular mechanism of penile erection in monkeys. Neurourol Urodyn 13(1):71-80
182. Turko IV, Francis SH, Corbin JD (1998) Potential roles of conserved amino acids in the catalytic domain of the cGMP-binding cGMP-specific phosphodiesterase. J Biol Chem 273(11):6460-6466
183. Turko IV, Ballard SA, Francis SH, Corbin JD (1999) Inhibition of cyclic GMP-binding cyclicGMP-specific phosphodiesterase (Type 5) by sildenafil and related compounds. Mol Pharmacol 56(1):124-130
184. Uckert S, Kuthe A, Jonas U, Stief CG (2001) Characterization and functional relevance of cyclic nucleotide phosphodiesterase isoenzymes of the human prostate. J Urol 166(6):2484-2490
185. Uckert S, Stief CG, Jonas U (2003) Current and future trends in the oral pharmacotherapy of male erectile dysfunction. Expert Opin Investig Drugs 12(9):1521-1533
186. Uckert S, Ehlers V, Nuser V, Oelke M, Kauffels W, Scheller F, Jonas U (2005) In vitro functional responses of isolated human vaginal tissue to selective phosphodiesterase inhibitors. World J Urol 23(6):398-404
187. Uckert S, Oelke M, Stief CG, Andersson KE, Jonas U, Hedlund P (2006) Immunohistochemical distribution of cAMP- and cGMP-phosphodiesterase (PDE) isoenzymes in the human prostate. Eur Urol 49(4):740-745
188. Valente EG, Vernet D, Ferrini MG, Qian A, Rajfer J, Gonzalez-Cadavid NF (2003) L-arginine and phosphodiesterase (PDE) inhibitors counteract fibrosis in the Peyronie's fibrotic plaque and related fibroblast cultures. Nitric Oxide 9(4):229-244
189. Van Staveren WC, Steinbusch HW, Markerink-Van Ittersum M, Repaske DR, Goy MF, Kotera J, Omori K, Beavo JA, De Vente J (2003) mRNA expression patterns of the cGMP-hydrolyzing phosphodiesterases types 2, 5, and 9 during development of the rat brain. J Comp Neurol 467(4):566-580
190. Vandeput F, Wolda SL, Krall J, Hambleton R, Uher L, McCaw KN, Radwanski PB, Florio V, Movsesian MA (2007) Cyclic nucleotide phosphodiesterase PDE1C1 in human cardiac myocytes. J Biol Chem 282(45):32749-32757
191. Vemulapalli S, Watkins RW, Chintala M, Davis H, Ahn HS, Fawzi A, Tulshian D, Chiu P, Chatterjee M, Lin CC, Sybertz EJ (1996) Antiplatelet and antiproliferative effects of SCH 51866, a novel type 1 and type 5 phosphodiesterase inhibitor. J Cardiovasc Pharmacol 28(6):862-869
192. Wada H, Manganiello VC, Osborne JC, Jr. (1987) Analysis of the kinetics of cyclic AMP hydrolysis by the cyclic GMP-stimulated cyclic nucleotide phosphodiesterase. J Biol Chem 262(29):13938-13945
193. Wang H, Liu Y, Huai Q, Cai J, Zoraghi R, Francis SH, Corbin JD, Robinson H, Xin Z, Lin G, Ke H (2006) Multiple conformations of phosphodiesterase-5: implications for enzyme function and drug development. J Biol Chem 281(30):21469-21479
194. Wang H, Ye M, Robinson H, Francis SH, Ke H (2008) Conformational variations of both phosphodiesterase-5 and inhibitors provide the structural basis for the physiological effects of vardenafil and sildenafil. Mol Pharmacol 73(1):104-110
195. Wayman C, Phillips S, Lunny C, Webb T, Fawcett L, Baxendale R, Burgess G (2005) Phosphodiesterase 11 (PDE11) regulation of spermatozoa physiology. Int J Impot Res 17(3):216-223
196. Weeks JL, Zoraghi R, Beasley A, Sekhar KR, Francis SH, Corbin JD (2005) High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients. Int J Impot Res 17(1):5-9
197. Weeks JL, II, Zoraghi R, Francis SH, Corbin JD (2007) N-Terminal domain of phosphodiesterase- 11A4 (PDE11A4) decreases affinity of the catalytic site for substrates and tadalafil, and is involved in oligomerization. Biochemistry 46(36):10353-10364
198. Wu AY, Tang XB, Martinez SE, Ikeda K, Beavo JA (2004) Molecular determinants for cyclic nucleotide binding to the regulatory domains of phosphodiesterase 2A. J Biol Chem 279(36):37928-37938
199. Wunder F, Tersteegen A, Rebmann A, Erb C, Fahrig T, Hendrix M (2005) Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line. Mol Pharmacol 68(6):1775-1781
200. Xu RX, Hassell AM, Vanderwall D, Lambert MH, HolmesWD, Luther MA, Rocque WJ, Milburn MV, Zhao Y, Ke H, Nolte RT (2000) Atomic structure of PDE4: insights into phosphodiesterase mechanism and specificity. Science 288(5472):1822-1825
201. Xu RX, Rocque WJ, Lambert MH, Vanderwall DE, Luther MA, Nolte RT (2004) Crystal structures of the catalytic domain of phosphodiesterase 4B complexed with AMP, 8-Br-AMP, and rolipram. J Mol Biol 337(2):355-365
202. Yan C, Zhao AZ, Bentley JK, Beavo JA (1996) The calmodulin-dependent phosphodiesterase gene PDE1C encodes several functionally different splice variants in a tissue- specific manner. J Biol Chem 271:25699-25706
203. Yuasa K, Kotera J, Fujishige K, Michibata H, Sasaki T, Omori K (2000) Isolation and characterization of two novel phosphodiesterase PDE11A variants showing unique structure and tissuespecific expression. J Biol Chem 275(40):31469-31479
204. Zhang KY, Card GL, Suzuki Y, Artis DR, Fong D, Gillette S, Hsieh D, Neiman J, West BL, Zhang C, Milburn MV, Kim SH, Schlessinger J, and Bollag G (2004) A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol Cell 15(2):279-286
205. Zhang KYJ (2006) Crystal structure of phosphodiesterase families and the potential for rational drug design. In: Beavo J, Francis SH, Houslay MD (eds) Cyclic nucleotide phosphodiesterase in health and disease. CRC Press, Boca Raton, pp 583-605
206. Zhang L, Zhang RL,Wang Y, Zhang C, Zhang ZG, Meng H, ChoppM(2005a) Functional recovery in aged and young rats after embolic stroke: treatment with a phosphodiesterase type 5 inhibitor. Stroke 36(4):847-852
207. Zhang X, Feng Q, Cote RH (2005b) Efficacy and selectivity of phosphodiesterase-targeted drugs in inhibiting photoreceptor phosphodiesterase (PDE6) in retinal photoreceptors. Invest Ophthalmol Vis Sci 46(9):3060-3066
208. Zhang RL, Zhang Z, Zhang L, Wang Y, Zhang C, Chopp M (2006) Delayed treatment with sildenafil enhances neurogenesis and improves functional recovery in aged rats after focal cerebral ischemia. J Neurosci Res 83(7):1213-1219
209. Zhao AZ, Yan C, SonnenburgWK, Beavo JA (1997a) Recent advances in the study of Ca2+/CaMactivated phosphodiesterases: expression and physiological functions. Adv Second Messenger Phosphoprotein Res 31:237-251
210. Zhao AZ, Zhao H, Teague J, Fujimoto W, Beavo JA (1997b) Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B. Proc Natl Acad Sci USA 94(7):3223-3228
211. Zhao AZ, Bornfeldt KE, Beavo JA (1998) Leptin inhibits insulin secretion by activation of phosphodiesterase 3B. J Clin Invest 102(5):869-873
212. Zhao AZ, Huan JN, Gupta S, Pal R, Sahu A (2002) A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nat Neurosci 5(8):727-728
213. Zoraghi R, Bessay EP, Corbin JD, Francis SH (2005) Structural and functional features in human PDE5A1 regulatory domain that provide for allosteric cGMP binding, dimerization, and regulation. J Biol Chem 280(12):12051-12063
214. Zoraghi R, Francis SH, Corbin JD (2007) Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cGMP and inhibitors. Biochemistry 46: 13554-13563